Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
With
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have a diagnosis of non-B-cell, non-Hodgkin's lymphoma (including T-cell, null-cell, or NK-cell lymphoma, but excluding lymphoblastic lymphoma)
Stage II, III, or IV disease requiring chemotherapy
At least one site of measurable disease, 1.5 cm in diameter or greater
Age \> or = 18 years
Absolute granulocyte count of at least 1500 cells/mm3, unless neutropenia is due to marrow infiltration by the tumor
Platelet count of at least 100,000 cells/mm3 unless thrombocytopenia is due to marrow infiltration by tumor
Creatinine less than 2 x upper limits of normal (ULN)
Total bilirubin less than 2 x ULN (dose reduced vincristine and adriamycin required for bilirubin \> 1.2 mg/dL)
Echocardiogram (Echo) or multiple gate acquisition scan (MUGA) documenting a normal ejection fraction prior to chemotherapy
Able to give informed consent
You may not be if
Known central nervous system (CNS) involvement
Known HIV disease
Patients who are pregnant or nursing
Any factor which might limit the patient's ability to provide informed consent
Life expectancy \< 3 months
Patients who are unwilling to agree to use an effective means of birth control while on treatment
Clareo Health | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
